Introduction {#s1}
============

The etiological agents of the complex of South American arenaviral hemorrhagic fevers are a group of closely related New World mammarenaviruses (NWMs) including Junín, Machupo, Guanarito, Sabiá and Chapare. These viruses are maintained in nature through persistent infections of their respective host rodent species ([@bib49]). Transmission of these agents to humans occurs through inhalation of aerosolized virus particles or contact with virus-containing rodent secreta or excreta ([@bib9]). Junín virus (JUNV) is the most prevalent of pathogenic NWMs and is the etiological agent of Argentine hemorrhagic fever (AHF). AHF is an insidious disease characterized by severe hemorrhagic and/or neurologic manifestations with remittent fever, tremors, vascular leak and shock ([@bib15]; [@bib18]; [@bib20]; [@bib21]). The pathogenesis of AHF is poorly understood; however, a salient feature of severe disease is an elevation in serum interferon-α (IFN-α) and other inflammatory mediators ([@bib40]; [@bib36]; [@bib37]; [@bib28]). The case-fatality rate of AHF can be as high as 30% in untreated individuals and the only countermeasures available for the prevention and treatment of severe JUNV infections are the Candid \#1 vaccine and convalescent plasma ([@bib21]). Neither has been approved for use outside of the area of endemicity and recent studies suggest that reversion to virulence by the vaccine virus can occur through a single nucleotide change in the envelope glycoprotein gene ([@bib62]; [@bib55]; [@bib1]).

Animal models are essential to gaining insights into viral pathogenesis. Several species of non-human primates are susceptible to lethal JUNV disease ([@bib32]; [@bib41]; [@bib2]). These models are considered the 'gold standard' because JUNV infection in these species more closely recapitulates the human disease. However, these models are costly and require specialized primate housing facilities within maximum biocontainment. Few small-animal models for JUNV exist because most standard laboratory rodent species, such as mice and hamsters, are refractory to severe disease. The most commonly used rodent model for JUNV is the guinea pig, which has served as the primary animal model to investigate pathogenesis and for screening promising therapeutic interventions ([@bib64]; [@bib26]; [@bib65]). However, the use of this model for investigations into JUNV pathogenesis and countermeasure development has been mired by the lack of commercial reagents for this species.

A feature specific to the pathogenic NWMs is the use of human transferrin receptor 1 (hTfR1) for cellular entry ([@bib46]; [@bib27]). In addition, different species known to be susceptible to disease following challenge with pathogenic NWMs express TfR1 orthologs that bind the viral envelope glycoprotein facilitating entry ([@bib27]; [@bib29]). These findings suggest that the use of TfR1 for viral attachment and entry is an important determinant in defining whether a NWM can cause severe disease in a species other than the respective rodent reservoir host. Based on this, we investigated whether the expression of hTfR1 in laboratory mice would render them susceptible to lethal disease following JUNV challenge. Here, we demonstrate that transgenic hTfR1 mice develop a lethal disease course when exposed to the pathogenic Romero strain of JUNV and characterize the natural history and pathogenesis of disease. We also show that the type I IFN response plays a central role in the development of severe JUNV infection and disease in mice expressing hTfR1. The development of the hTfR1 mouse model of JUNV infection provides a novel system to investigate viral pathogenesis and assess promising therapeutics.

Results {#s2}
=======

Susceptibility of hTfR1 mice to JUNV infection {#s2-1}
----------------------------------------------

Wild-type (WT) mice are refractory to disease following JUNV challenge ([@bib22]). To investigate whether expression of hTfR1 would confer susceptibility to disease following JUNV infection, groups of 3-week-old WT, hTfR1 heterozygous (HET) and hTfR1 homozygous (HOM) mice were challenged by intraperitoneal (i.p.) injection with a 10^5^ fifty percent cell culture infectious dose (CCID~50~) of JUNV, or sham-infected, and observed for mortality and weight change ([Figure 1A and B](#fig1){ref-type="fig"}). On day 8 post-infection (p.i.), initial signs of lethargy and ruffling of fur accompanied weight loss in the cohort of hTfR1 HOM mice, which increased in severity until they succumbed to infection by day 16 p.i. JUNV disease was also observed in the hTfR1 HET mice but to a lesser degree with the mice exhibiting stagnated weight gain beginning on day 9 p.i with a single animal requiring euthanasia due to severe neurologic signs on day 14 p.i. In contrast, the WT mice showed no visibly apparent signs of illness, suggesting that expression of hTfR1 was necessary for the development of JUNV disease.

![Expression of hTfR1 results in severe disease following JUNV infection.\
Three-week-old WT, hTfR1 HET or hTfR1 HOM mice (*n* = 8--9/group) were infected i.p. with 10^5^ CCID~50~ of JUNV and monitored daily. (**A**) Survival and (**B**) weight change of animals relative to the day of virus challenge (group mean and standard error of the mean; SEM) are shown. Sham-infected controls (*n* = 6) consisted of a mix of WT, hTfR1 HET and hTfR1 HOM hTfR1 mice. Aggregate data from two independent experiments. \*\*\*p=0.0003 and \*\*\*\*p\<0.0001 compared to hTfR1 HOM mice.\
Figure 1---source data 1.](elife-55352-fig1){#fig1}

Age- and dose-dependent susceptibility of hTfR1 mice to lethal JUNV infection {#s2-2}
-----------------------------------------------------------------------------

To gain further insight into the susceptibility of hTfR1 HOM mice to lethal JUNV infection, groups of 3, 4, 5 and 6-week-old animals were challenged i.p. with 10^5^ CCID~50~ of JUNV and observed for morbidity and mortality. The mice were also scored for clinical disease signalment to further characterize the disease course and presentation. As shown in [Figure 2](#fig2){ref-type="fig"}, susceptibility to JUNV disease decreased with age. Beginning one-week p.i., the 3-week-old mice started to display clinical disease signs accompanied by weight loss and uniform lethality by day 13 p.i. ([Figure 2A,B and D](#fig2){ref-type="fig"}). In the 4-week-old animals, clinical disease signs and stagnation in weight gain started to develop by day 8 p.i., with one animal succumbing to infection 13 days after JUNV challenge ([Figure 2A,B and D](#fig2){ref-type="fig"}). No mortality was observed in the 5-week-old animals despite notable weight loss and other signs of disease starting on day 8 p.i. ([Figure 2A,C and D](#fig2){ref-type="fig"}). There was no evidence of weight loss or observable clinical signs in the 6-week-old mice ([Figure 2C and D](#fig2){ref-type="fig"}).

![Age-dependent susceptibility of hTfR1 HOM mice to lethal JUNV disease.\
Shown are (**A**) survival (*n* = 6/group for the 3- and 4-week-old mice, *n* = 3/group for the 5- and 6-week-old mice), (**B**) weight change in 3 to 4 week-old mice, (**C**) weight change in 5 to 6 week-old mice and D) clinical disease scores for each group infected i.p. with 10^5^ CCID~50~ of JUNV. Open symbols in the weight change graphs indicate age-matched sham-infected controls (*n* = 3). The weight data are represented as the group mean and SEM of the percent change in weight of animals relative to their starting weights on the day of virus challenge. Clinical scoring is expressed as group mean and SEM. \*p=0.0448 compared to age-matched sham-infected controls.\
Figure 2---source data 1.](elife-55352-fig2){#fig2}

Based on their susceptibility to lethal disease following JUNV challenge, we sought to determine the 50% and 90% lethal challenge doses (LD~50~ and LD~90~, respectively) in 3-week-old hTfR1 HOM mice. Groups of mice were challenged i.p. with serial log~10~ dilutions of JUNV (10^5^, 10^4^ and 10^3^ CCID~50~) or sham-infected and observed for weight loss, other clinical disease signs and mortality. A JUNV challenge of 10^5^ or 10^4^ CCID~50~ resulted in uniform lethality by 15 and 18 days p.i., respectively, while 2 of 7 animals survived a challenge dose of 10^3^ CCID~50~ ([Figure 3A](#fig3){ref-type="fig"}). The onset of weight loss and other clinical disease signs also occurred in a dose-dependent manner, with animals challenged with higher doses of virus developing disease earlier in the course of infection ([Figure 3B and C](#fig3){ref-type="fig"}). All animals inoculated with a challenge dose of 10^5^ CCID~50~ started losing weight and exhibiting other clinical disease signs such as ruffled fur and lethargy by day 8 p.i. ([Figure 3B and C](#fig3){ref-type="fig"}). A one- to two-day delay in weight loss and other disease signs was observed in the groups challenged with 10^4^ and 10^3^ CCID~50~ of JUNV, respectively. Based on the mortality results in 3-week-old hTfR1 HOM mice, the JUNV LD~50~ was less than 1000 CCID~50~ and the LD~90~ was calculated to be 3793 CCID~50~.

![JUNV lethal dose determination in 3-week-old hTfR1 HOM mice.\
Shown are (**A**) survival (*n* = 7/JUNV challenge group, *n* = 3 sham-infected controls), (**B**) weight change relative to the day of virus challenge (group mean and SEM) and (**C**) clinical disease scores (group mean and SEM) for groups of mice infected i.p. with 10^5^, 10^4^ or 10^3^ CCID~50~ of JUNV or sham-infected. LD~90~ = 3793; LD~50~ \<1000 CCID~50~.\
Figure 3---source data 1.](elife-55352-fig3){#fig3}

Natural history and pathogenesis of JUNV infection in hTfR1 mice {#s2-3}
----------------------------------------------------------------

To gain insight into the pathogenesis of JUNV in the hTfR1 HOM mice, a natural history study was designed to investigate several virologic, clinical and laboratory parameters during the course of infection. To ensure uniform lethality, a challenge dose of 10^4^ CCID~50~ was administered i.p. to 3-week-old animals. As shown in [Figure 4A](#fig4){ref-type="fig"}, the JUNV-challenged mice began to plateau in weight gain on day 9 p.i. and started to lose weight by day 10 p.i. Clinical disease signs were observed in a few mice as early as day 8 p.i., which corresponded with a sharp increase in serum IFN-α concentration ([Figure 4B and C](#fig4){ref-type="fig"}). By day 12 p.i., all mice in the day 12 sacrifice group had succumbed, with only 2 of 4 animals remaining in the group scheduled for sacrifice on day 14 p.i. These 2 mice were moribund and therefore euthanized on day 12 p.i. and assessed for IFN-α levels, viremia and tissue viral burden. High systemic concentrations of IFN-α were present in the serum of all JUNV-infected animals by day 10 p.i., with peak concentrations observed in the moribund day-12 mice ([Figure 4C](#fig4){ref-type="fig"}). The virus was first detected in the liver, spleen and brain on day 6 p.i. ([Figure 4D](#fig4){ref-type="fig"}). Thereafter, viral loads generally continued to increase and were detectable in other organs as the infection progressed. Viremia was undetectable in the mice until day 10 p.i. ([Figure 4D](#fig4){ref-type="fig"}). The two moribund mice that were euthanized on day 12 p.i. had substantial viral loads in serum and all tissues analyzed.

![Temporal analysis of weight change, clinical disease signs, IFN-α and viral burden during the course of JUNV infection in 3-week-old hTfR1 HOM mice.\
Animals (*n* = 28) were infected i.p. with 10^4^ CCID~50~ of JUNV and subsets of 4 mice were designated for euthanasia on days 2, 4, 6, 8, 10, 12 and 14 p.i. for blood and tissue collection and analysis. Due to death prior to sample collection on days 12 and 14, only 2 mice were available on day 12. Four sham-infected animals were included as controls and 3 (one per day) were euthanized on days 2, 6 and 10 for sample collection. (**A**) Weight change of animals relative to the day of virus challenge, (**B**) clinical disease scores (mean and SEM), (**C**) serum IFN-α concentrations and (**D**) tissue and serum viral titers (the x-axis represents the limit of detection) are shown. \*\*p=0.0060, \*\*\*\*p\<0.0001 compared to sham-infected normal controls. SI, sham-infected.\
Figure 4---source data 1.](elife-55352-fig4){#fig4}

Microscopic analysis revealed neutrophilic encephalitis and individual cell death (necrosis or apoptosis) in the brain and in the splenic red and white pulps in infected mice as early day 10 p.i. (not shown) with more moderate to severe lesions seen on day 12 p.i. ([Figure 5](#fig5){ref-type="fig"}). The splenic red and white pulp organization was normal, but mild to moderate individual cell necrosis or apoptosis was present in the white pulp and, to a lesser extent, in the red pulp ([Figure 5F and H](#fig5){ref-type="fig"}). The dead cells were presumed to be mainly lymphocytes or macrophages given the location in the white pulp. Immunohistochemistry (IHC) for JUNV antigen was performed on mice euthanized on day 12 p.i. Strong cytoplasmic immunoreactivity was present in neurons multifocally and randomly within the midbrain ([Figure 6B and D](#fig6){ref-type="fig"}), as well as the cerebral cortex, thalamus and hypothalamus (not shown). Moderate to strong cytoplasmic immunoreactivity was observed in mononuclear cells, mainly within the white pulp of the spleen ([Figure 6F and H](#fig6){ref-type="fig"}). JUNV antigen was not detected in the kidney, liver, intestine or lung tissue (not shown). The lack of IHC staining for viral antigen in certain tissues with measurable infectious viral loads may be due to a delay in the accumulation of JUNV antigen detectable by IHC, masking of antigen by prolonged formalin fixation of tissues and/or the sensitivity of the IHC staining technique.

![Histopathology in 3-week-old hTfR1 HOM mice infected with JUNV.\
Representative sections of brain (cerebral cortex) from (**A** and **C**) a sham-infected mouse and (**B** and **D**) a JUNV-infected mouse at day 12 p.i. (**B**) Neutrophilic encephalitis characterized by a perivascular cuff of inflammatory cells (arrow) and neutrophilic infiltration in the neuropil (arrowhead). (**D**) Higher magnification image showing necrotic cells (arrows) and neutrophils (arrowhead) within the neuropil. (**E** and **G**) Spleen (white pulp) from a sham-infected control mouse. (**F** and **H**) Spleen (white pulp) of a JUNV-infected mouse at day 12 p.i. (**F**) Tingible body macrophages (arrow) and individual lymphocyte cell death (arrowhead) are scattered within a periarteriolar lymphoid sheath. (**H**) Higher magnification image showing tingible body macrophages with cytoplasmic engulfed apoptotic debris (arrow) and individual lymphocyte cell death (arrowhead). Hematoxylin and eosin stain. **A, B, E** and **F**: 400 × magnification, bar = 50 μm. **C, D, G** and **H**: 1000 × magnification, bar = 20 μm.](elife-55352-fig5){#fig5}

![Immunohistochemistry for JUNV antigen in 3-week-old hTfR1 HOM mice.\
Representative sections of brain (midbrain) from (**A** and **C**) a sham-infected mouse and (**B** and **D**) a JUNV-infected mouse at day 12 p.i. Note the presence of the virus in neurons (brown staining). (**E** and **G**) Spleen (white pulp) from a sham-infected control mouse. (**F** and **H**) Virus antigen in mononuclear cells in the spleen (white pulp) of a JUNV-infected mouse at day 12 p.i. Hematoxylin counterstain. **A, B, E** and **F**: 400 × magnification, bar = 50 μm. **C, D, G** and **H**: 1000 × magnification, bar = 20 μm.](elife-55352-fig6){#fig6}

Contribution of the type I IFN response in JUNV pathogenesis in hTfR1 mice {#s2-4}
--------------------------------------------------------------------------

Severe cases of AHF are associated with elevated concentrations of serum IFN-α, which may contribute to disease severity ([@bib36]; [@bib37]). To investigate whether the type I IFN response contributes to the development of severe disease in hTfR1 HOM mice, we challenged cohorts of animals representing 6 different genetic backgrounds with JUNV. As expected, challenge of hTfR1 HOM mice with JUNV resulted in significant clinical disease, which progressed to uniform lethality within 2 weeks of infection ([Figure 7A--C](#fig7){ref-type="fig"}). In contrast, illness was not observed in hTfR1 HOM--IFN-α/β receptor (R)-deficient or hTfR1 HOM--IFN-α/β and -γR-deficient mice. At day 28 p.i., serum and tissue were collected from the surviving animals and titrated for infectious viral loads. JUNV was undetectable in WT mice and was present only in brain tissue of IFN-α/βR-deficient mice ([Figure 7D](#fig7){ref-type="fig"}). In contrast, IFN-α/β and -γR-deficient mice, and both IFN-α/βR and IFN-α/β and -γR-deficient mice expressing hTfR1, were harboring JUNV in most tissues.

![Effect of type I and II IFN response on JUNV infection and disease outcome in 3-week-old hTfR1 HOM mice.\
Mice (*n* = 3/group) of different phenotypic backgrounds were challenged with 10^5^ CCID~50~ of JUNV and monitored daily for (**A**) survival, (**B**) weight change relative to the day of virus challenge (group mean and SEM), (**C**) clinical disease (group mean and SEM) and (**D**) tissue viral loads present on day 28 p.i. in surviving animals (virus was not detected in serum or intestine or in any WT mice). The x-axis represents the virus titer assay limit of detection. \*p=0.0246 compared to WT mice or all other phenotypes.\
Figure 7---source data 1.](elife-55352-fig7){#fig7}

Because of the hybrid background of the genotypic variants of mice used in the initial experiment to assess the role of the type I IFN response in JUNV pathogenesis, we could not rule out the contribution of genetic variation to susceptibility to JUNV infection, disease and persistence. Thus, to further investigate the role of type I IFN in the lethal disease outcome in hTfR1 HOM mice, JUNV infection in the presence of temporary antibody-mediated blockade of type I IFN receptors was pursued. Administration of anti-IFN-α/βR monoclonal antibodies (mAbs) as a single dose the day prior to JUNV challenge, with or without additional maintenance dosing to continue to suppress the type I IFN response, was sufficient to protect hTfR1 HOM mice from lethal disease ([Figure 8A](#fig8){ref-type="fig"}). Notably, one of the mAb-treated mice in the one-week treatment group was euthanized on day 13 p.i. due to the development of recurring seizures of unknown etiology. While the vehicle placebo-treated animals displayed notable weight loss (\>10%) and other disease signs starting on day 9 p.i., clinical disease was not observed in any of the anti-IFN-α/βR mAb-treated mice ([Figure 8B and C](#fig8){ref-type="fig"}). To a lesser extent than observed in the previous experiment in hTfR1 HOM mice lacking type I and type II IFN receptors, JUNV persisted in apparently healthy mAb-treated mice at the conclusion of the study ([Figure 8D](#fig8){ref-type="fig"}). Collectively, the findings from these two experiments indicate that the type I IFN response plays a central role in the development of severe disease associated with JUNV infection in mice expressing hTfR1.

![Effect of anti-IFN-α/βR mAb treatment on JUNV pathogenicity in 3-week-old hTfR1 HOM mice.\
Animals (*n* = 3--4/group) were treated with a single 500 µg dose of IFN-α/βR-blocking mAb (with or without additional 250 µg maintenance doses every other day for one or two weeks) and infected i.p. the following day with 10^5^ CCID~50~ of JUNV. The mice were monitored daily for (**A**) survival, (**B**) weight change relative to the day of virus challenge (mean and SEM), (**C**) clinical disease (mean and SEM) and (**D**) tissue viral loads in surviving animals on day 28 p.i. (virus was undetectable in serum, liver, lung, heart and intestine). The x-axis represents the virus titer assay limit of detection. \*p=0.0114 comparing the two-week placebo treatment to the single and one-week mAb treatments; \*p=0.0238 comparing the two-week placebo treatment to the two-week mAb treatment. Tx, treatment.\
Figure 8---source data 1.](elife-55352-fig8){#fig8}

Discussion {#s3}
==========

The first step in the viral infection process is the interaction between the virion and its host cell receptor. Pathogenic NWMs infect cells of their natural rodent reservoir via the endogenous TfR1 ([@bib66]; [@bib47]). These viruses have, in addition, adapted to utilize hTfR1 as the principal entry receptor in human cells ([@bib46]). Related NWMs that enter through TfR1-independent mechanisms do not cause disease in humans ([@bib50]). Moreover, species known to be susceptible to disease when challenged with pathogenic NWMs (guinea pigs, marmosets, macaques) express TfR1 orthologs capable of mediating attachment and cellular entry ([@bib27]; [@bib29]). By contrast, species that are refractory to pathogenic NWM infection (laboratory mice and hamsters) express TfR1 orthologs that do not support virus entry ([@bib29]; [@bib47]). Taken together, these findings suggest that the ability of NWMs to use TfR1 for entry is an important determinant in defining species vulnerability to severe disease ([@bib10]). In the present study, we tested the hypothesis that mice genetically engineered to express hTfR1 would be susceptible to disease following exposure to JUNV. While hTfR1 HET mice were more susceptible to moderate JUNV disease than their WT counterparts, the development of uniformly lethal disease required the homozygous expression of hTfR1. The more severe disease phenotype was likely due to higher levels of hTfR1 in the liver and other tissues in the hTfR1 HOM mice compared to hTfR1 HET littermates ([@bib63]). The susceptibility of hTfR1 HOM mice to lethal JUNV infection was age-dependent as the animals developed resistance as they matured. Several mechanisms may be involved in the development of resilience to JUNV challenge including a reduction in target receptor expression levels as mice age ([@bib30]; [@bib16]; [@bib38]; [@bib53]) and the maturation of the immune response ([@bib13]; [@bib5]; [@bib4]; [@bib6]; [@bib17]; [@bib14]; [@bib33]). Additional studies are needed to investigate the age-dependent susceptibility of hTfR1 mice to JUNV and other New World hemorrhagic fever mammarenaviruses.

The type I IFN response plays an important role in protecting the host against viral pathogens; however, recent studies in mice characterizing the pathogenesis of acute infection by lymphocytic choriomeningitis virus (LCMV), a related mammarenavirus, have shown that the response can also contribute to lethal disease ([@bib43]; [@bib3]). In the natural history and pathogenesis study characterizing JUNV infection and disease in hTfR1 HOM mice, we found that serum levels of IFN-α began to spike on day 8 p.i., just before the onset of clinical disease signs. Notably, patients suffering from AHF have been found to have increased concentrations of circulating IFN-α, which is believed to contribute to the clinical disease manifestations ([@bib36]; [@bib37]). The type I IFN response (IFN-α and IFN-β), which is a critical element of the innate immune response to throttle viral infections prior to the development of the adaptive immune response, can also have a damaging effect on the host when elevated systemic levels of type I IFN persist ([@bib35]; [@bib54]). Type I IFN signaling can impair immune system function by enhancing the expression of immunosuppressive molecules and inducing immune cell apoptosis ([@bib56]), which has been shown to affect the development of an effective adaptive immune response and contributes to the inability of the host to resolve persistent LCMV infections ([@bib57]; [@bib61]). In lethal NZB and FVB/N mouse infection models based on intravenous challenge with 2 × 10^6^ plaque-forming units of the Clone 13 (Cl13) LCMV variant, type I IFN was found to underlie the severe disease phenotype ([@bib43]; [@bib3]). Similarly, in hTfR1 HOM mice lacking IFN-α/βR or IFN-α/β and -γ receptors, or hTfR1 HOM mice treated with mAbs that block the IFN-α/βR, we demonstrate the essential role of the type I IFN response in driving JUNV pathogenesis. Deletion of the CD8 T cell response also prevents lethality associated with LCMV Cl13 infection in NZB and FVB/N mice ([@bib43]; [@bib51]). The role of cytotoxic and helper T cells in JUNV pathogenesis in hTfR1 was not defined in the present study, but comparisons to the NZB and FVB/N models are complicated by differences in mouse age and genetics, as well as the virus challenge route and infectious doses administered. With respect to the latter, the outcome of infection (persistence vs. immune-mediated lethality) with LCMV Cl13 in C57BL/6 mice could be manipulated by modifying the virus challenge dose ([@bib58]; [@bib12]).

Mammarenaviruses are well known for their ability to cause persistent infections in rodents. Despite the lack of observable disease in the absence of IFN-α/β or IFN-α/β and -γ receptors, or following temporary mAb blockade of the IFN-α/βR, JUNV was able to persist in hTfR1 mice for up to 28 days in multiple tissues. It is likely that in the absence of type I IFN signaling JUNV infection would persist for an extended period (60 days), similar to that observed in Cl13 LCMV-infected mice protected from lethal disease through mAb treatment to block IFN-α/βR signaling ([@bib43]). Also of note, JUNV persisted in multiple tissues of IFN-α/β and -γR-deficient mice expressing native mouse TfR1, while viral persistence in IFN-α/βR-deficient mice expressing mouse TfR1 was only evident in the brain. Consistent with the antiviral role of IFN-γ ([@bib52]), the dual type I and type II IFN receptor deficiency was more permissive to persistence regardless of whether or not hTfR1 was present. Further studies investigating long-term persistence and whether JUNV is shed in fecal matter and urine are needed to shed light on the potential virus-host carrier state that may result from infection in hTfR1 mice with compromised type I IFN responses.

In humans, mammarenaviral hemorrhagic fever is generally associated with mild pathological changes ([@bib44]). JUNV infection in hTfR1 mice resulted in limited histologic lesion development observed only during advanced stages of disease. Cell death of splenic mononuclear cells was present in mice at 10 and 12 days p.i. This lesion has been observed in other animal models of JUNV infection and natural infection in humans ([@bib59]; [@bib31]; [@bib23]; [@bib7]). In humans, JUNV has been detected in phagocytic cells but not lymphocytes ([@bib23]). In hTfR1 mice, the presence of JUNV antigen in the spleen was detected mainly in the white pulp suggesting a cytopathic effect on mononuclear cells. Similar findings have also been observed in the guinea pig model for JUNV ([@bib64]), which suggests that targeting of mononuclear phagocytes may be central to pathogenesis. Death of the hTfR1 mice was tentatively attributed to neutrophilic encephalitis with JUNV antigen detected in neurons. Encephalitis has been reported in primates and humans infected with JUNV ([@bib24]; [@bib60]). Increased vascular permeability and prominent histopathology are features observed with LCMV Cl13 infection in NZB and FVB/N mice that succumb from respiratory failure and shock ([@bib43]; [@bib3]; [@bib51]; [@bib45]). Additional studies are needed to determine whether vascular leak associated with excess and prolonged proinflammatory cytokine concentrations, including IFN-α, may also be contributing to the demise of the JUNV-infected hTfR1 HOM mice.

The use of hTfR1 as the primary cellular entry receptor renders the pathogenic NWMs vulnerable to the development of countermeasures that interfere with the interaction between the viral envelope glycoprotein GP1 attachment subunit and the host cell receptor. The region of hTfR1 that mediates binding to the ectodomain of GP1 is the apical domain, which is not involved in binding to the known principal ligands, transferrin and hemochromatosis protein ([@bib8]; [@bib34]; [@bib42]), thus representing a potential host-directed therapeutic target to broadly inhibit infection by JUNV and other New World hemorrhagic fever mammarenaviruses. Recent advances to exploit this vulnerability include the identification of a mAb (ch128.1) and an aptamer that bind to the apical domain of hTfR1 and the development of an immunoadhesin with the sequence of white-throated woodrat TfR1 apical domain fused to the Fc region of an IgG which binds to pathogenic NWM GP1 ([@bib27]; [@bib39]; [@bib11]). Until now, proof-of-concept experiments to determine whether the ch128.1 strategy would prove to be an effective host-directed therapeutic to broadly treat NWM hemorrhagic fever were not possible due to the lack of an appropriate small-animal model. The novel hTfR1 mouse JUNV infection model that we have developed will be a valuable system in which this type of specific intervention can be investigated due to the requirement of hTfR1. Moreover, the new mouse model also provides an alternative to evaluate experimental therapies that directly target attachment by JUNV and related pathogenic NWMs and benefits from the large number of validated mouse reagents to assess immunological parameters and other physiological processes. By comparison, studies using the guinea pig JUNV infection model are limited by a shortage of reagents, animal costs and the requirement for substantially higher quantities of investigational drugs, which is often a limiting factor during early stages of antiviral drug discovery and development.

In summary, our findings identify hTfR1-mediated entry and the type I IFN response as key factors in the development of lethal JUNV disease in mice. The development of the first mouse model of JUNV infection in immunocompetent mice will be useful for investigating JUNV pathogenesis and early preclinical development of promising therapeutic interventions including approaches that disrupt the pathogenic NWM GP1-hTfR1 apical domain interaction. In addition, the identification of the type I IFN response as a key element in the development of severe JUNV disease in hTfR1 mice further supports investigation and development of immune-modulating agents as potential therapies to limit disease severity in cases of AHF and other NWM hemorrhagic fevers.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                             Designation                                                                            Source or\                                    Identifiers                                                                      Additional\
  (species) or\                                                                                                                    reference                                                                                                                      information
  resource                                                                                                                                                                                                                                                        
  ----------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------
  Genetic reagent (*Mus musculus*)          C57BL/6 hTfR1 knock-in mice (human *TFRC* replacing the mouse *Tfrc*)                  Genentech                                                                                                                      

  Genetic reagent (*Mus musculus*)          AG129 mice deficient in IFN-α/β receptor (R) and IFN-γR (*Ifnar*^-/-^; *Ifngr*^-/-^)   Washington\                                                                                                                    
                                                                                                                                   University Medical School                                                                                                      

  Genetic reagent (*Mus musculus*)          Wild-type (WT) mice (hybrid C57BL/6 × 129 background)                                  This paper                                                                                                                     See Materials and methods

  Genetic reagent (*Mus musculus*)          hTfR1 heterozygous (HET) mice (hybrid C57BL/6 × 129 background)                        This paper                                                                                                                     See Materials and methods

  Genetic reagent (*Mus musculus*)          hTfR1 homozygous (HOM) mice (hybrid C57BL/6 × 129 background)                          This paper                                                                                                                     See Materials and methods

  Genetic reagent (*Mus musculus*)          IFN-α/βR-deficient mice (hybrid C57BL/6 × 129 background)                              This paper                                                                                                                     See Materials and methods

  Genetic reagent (*Mus musculus*)          IFN-α/β and -γR-deficient mice (hybrid C57BL/6 × 129 background)                       This paper                                                                                                                     See Materials and methods

  Genetic reagent (*Mus musculus*)          hTfR1 HOM--IFN-α/βR-deficient mice (hybrid C57BL/6 × 129 background)                   This paper                                                                                                                     See Materials and methods

  Genetic reagent (*Mus musculus*)          hTfR1 HOM--IFN-α/β and -γR-deficient mice (hybrid C57BL/6 × 129 background)            This paper                                                                                                                     See Materials and methods

  Strain, strain background (Junín virus)   Recombinant JUNV Romero strain                                                         University of Texas Medical Branch                                                                                             

  Cell line (*Cercopithecus aethiops*)      Vero                                                                                   ATCC                                          Cat\# CCL-81 RRID:[CVCL_0059](https://scicrunch.org/resolver/CVCL_0059)          

  Commercial assay or kit                   VeriKine Mouse Interferon Alpha ELISA Kit                                              PBL Assay Science                             Cat\# 42115--1                                                                   

  Antibody                                  Goat anti-mouse IgG1 Fab (polyclonal)                                                  Jackson ImmunoResearch Laboratories           Cat\# 115-007-185 RRID:[AB_2632498](https://scicrunch.org/resolver/AB_2632498)   (1:10)

  Antibody                                  Anti-JUNV nucleoprotein antibody (QC03-BF11)                                           BEI Resources                                 Cat\# NR-43775                                                                   (1:100)

  Antibody                                  Goat anti-mouse IgG (H+L) - HRP secondary antibody (polyclonal)                        Thermo Fisher Scientific                      Cat\# G-21040 RRID:[AB_2536527](https://scicrunch.org/resolver/AB_2536527)\      (1:100)

  Antibody                                  Anti-mouse IFNAR-1 (anti-IFN-α/βR) monoclonal antibody (MAR1-5A3)                      Bio X Cell                                    Cat\# BE0241 RRID:[AB_2687723](https://scicrunch.org/resolver/AB_2687723)        (500 µg primary dose; 250 µg maintenance dose)

  Software                                  GraphPad Prism software                                                                GraphPad Prism (<https://www.graphpad.com>)   RRID_SCR_002798                                                                  Version 8.4.1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Virus and cells {#s4-1}
---------------

The molecular clone of the Romero strain of JUNV ([@bib19]) was kindly provided by Dr. Slobodan Paessler (University of Texas Medical Branch, Galveston, TX). The virus stock (10^7^ CCID~50~/ml) was prepared from a single passage in Vero African green monkey kidney (ATCC CCL-81) cells (American Type Culture Collection, Manassas, VA) maintained in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Low-passage cells grown directly from the Vero stock generated from the first passage of the CCL-81 source vial obtained from ATCC were used for all experiments. The Vero cell stock was confirmed to be free of mycoplasma using the PlasmoTest -- Mycoplasma Detection Kit (InvivoGen, San Diego, CA). The virus stock was diluted in MEM vehicle to achieve the desired viral doses in a 0.1 ml volume. All work with JUNV was conducted in enhanced biosafety level 3+ containment facilities at USU by Candid\#1-vaccinated personnel.

Animals {#s4-2}
-------

C57BL/6 hTfR1 knock-in (human *TFRC* replacing the mouse *Tfrc*) mice were obtained from Genentech (San Francisco, California) and have been previously described ([@bib63]). Heterozygous (HET) hTfR1 mice were bred to produce homozygous (HOM) hTfR1 founders. The founding animals were backcrossed twice with AG129 mice, a 129/SvEv strain deficient in type I and type II IFN receptors (IFN-α/β and -γR-deficient), and the resulting hybrid animals were crossed to produce 1) WT, 2) hTfR1 HET, 3) hTfR1 HOM, 4) IFN-α/βR-deficient, 5) IFN-α/β and -γR-deficient, 6) hTfR1 HOM--IFN-α/βR-deficient and 7) hTfR1 HOM--IFN-α/β and -γR-deficient mice. The AG129 mice were kindly provided by Dr. Robert Shreiber (Washington University Medical School, St. Louis, MO). WT littermates and mice designated hTfR1 HET or hTfR1 HOM expressed both IFN-α/β and -γ receptors. All mice were genotyped for the presence or absence of mouse TfR1 and hTfR1 and type I and type II IFN receptors by PCR. Male and female animals were used in all studies.

Susceptibility of hTfR1 mice to lethal JUNV infection {#s4-3}
-----------------------------------------------------

In 2 separate experiments, hybrid 3-week-old WT, hTfR1 HET and hTfR1 HOM mice (*n* = 8--9/virus challenge group, *n* = 6 for the sham-infected control group which included 2 mice of each genotype) were inoculated with 10^5^ CCID~50~ of JUNV or sham-infected with MEM only via 0.1 ml i.p. injection. The number of mice per group was selected based on previous experience resolving differences in survival outcomes in uncharacterized rodent models of human viral diseases. Following JUNV challenge, the mice were weighed and observed daily for 21 days for morbidity and mortality. By 21 days p.i., survivors were generally recovering from the infection, as judged by normal activity and body condition.

Age-dependent susceptibility of hTfR1 HOM mice to lethal JUNV infection {#s4-4}
-----------------------------------------------------------------------

Cohorts of 3, 4, 5 and 6-week-old hTfR1 HOM mice (*n* = 6/JUNV infection group for the 3- and 4-week-old mice, *n* = 3/JUNV infection group for the 5- and 6-week-old mice and *n* = 3/age-matched sham-infected controls per age group) were challenged i.p. with 10^5^ CCID~50~ of JUNV or sham-infected with MEM vehicle. Following challenge, the mice were weighed and monitored daily for morbidity and mortality for 28 days. For this and all subsequent experiments, clinical signs of disease were scored as 0 (not present) or 1 (present) based on the presence of the following disease signs: weight loss exceeding 10% of peak weight, lethargy, hunched posture, ruffled fur, tremors, paralysis, distended abdomen and bleeding. Animals with a cumulative clinical score greater than 6, experiencing weight loss greater than 30% compared to peak weight or unresponsive to external stimulus, were euthanized.

Lethal dose determination in hTfR1 HOM mice {#s4-5}
-------------------------------------------

To determine the LD~50~ and LD~90~ of JUNV in hTfR1 HOM mice, groups of 3-week-old mice (*n* = 7/virus challenge dose, *n* = 3/sham-infected control group) were inoculated by i.p. injection with one of three serial log~10~ dilutions (10^5^, 10^4^ or 10^3^ CCID~50~) of JUNV or sham-infected with MEM. Mice were weighed the day before JUNV challenge and assigned to experimental groups to minimize sex and weight differences across the groups. For 28 days, the animals were weighed daily and assigned a score from 0 to 8 based on clinical signs of disease. The LD~50~ and LD~90~ values were calculated using Prism 8 (version 8.4.1; GraphPad, La Jolla, CA).

Natural history and pathogenesis of JUNV infection in hTfR1 HOM mice {#s4-6}
--------------------------------------------------------------------

Groups of 3-week-old hTfR1 mice were challenged with 10^4^ CCID~50~ of JUNV or sham-infected. Mice were weighed the day before virus challenge and assigned to experimental groups to minimize sex and weight differences across the groups. Cohorts of 4 animals/group were euthanized every other day beginning on day 2 p.i. No animals survived beyond 12 days p.i. A single sham-infected control mouse was euthanized each day on days 2, 6 and 10 p.i. During the course of the experiment and prior to euthanasia, mice were weighed and evaluated daily for clinical disease signs. Blood samples were collected by submandibular vein puncture to obtain serum for analysis of IFN-α concentration and viremia. Following euthanasia, mice were transcardially perfused with sterile phosphate-buffered saline (PBS) before tissue samples of brain, liver, spleen, lung, heart, kidney and intestine were collected for determination of viral load and histopathology.

Determination of tissue and serum viral loads {#s4-7}
---------------------------------------------

Viral loads in tissues and serum were assayed using an infectious cell culture assay, as previously described ([@bib25]). Briefly, tissues were homogenized in a fixed volume of MEM and the homogenates and serum were serially diluted and added to quadruplicate wells of Vero cell monolayers in 96-well microtiter plates. Viral cytopathic effect was determined 10 days p.i., and the 50% endpoints were calculated by the Reed and Muench method ([@bib48]). The assay limits of detection were 1.67 log~10~ CCID~50~ per ml of serum and 2.23 log~10~ CCID~50~/g of tissue.

Serum IFN-α analysis {#s4-8}
--------------------

Serum IFN-α concentration for each mouse was determined using the VeriKine Mouse Interferon Alpha ELISA Kit (PBL Assay Science, Piscataway, NJ). The assay was completed following the manufacturer's specifications.

Histopathology and immunohistochemistry (IHC) {#s4-9}
---------------------------------------------

Samples of brain, liver, spleen, lung, heart, kidney and intestine of hTfR1 mice collected at 2, 4, 6, 8, 10 and 12 days p.i. were preserved in 10% neutral buffered formalin. Fixed tissue samples were processed and embedded in paraffin according to routine histologic techniques. Tissue sections, 5 µm thick, were stained with hematoxylin and eosin and examined by light microscopy by a board-certified pathologist who was blinded to the groups and day of euthanasia. Tissue lesions severity were scored as follows: 0 = no lesions, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe. Formalin-fixed sections of spleen, liver, kidney, intestine, lung and brain from sham-infected and moribund JUNV-infected hTfR1 HOM mice at day 12 p.i. were also evaluated for the presence of JUNV antigen by IHC using a mouse mAb raised against the JUNV nucleoprotein (BEI Resources, Manassas, VA). Briefly, tissue sections were permeabilized with 0.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO) for 5 min and the endogenous peroxidase activity was blocked for 15 min with 3% hydrogen peroxide. Prior to incubation with the primary anti-JUNV nucleoprotein mAb, the slides were incubated with blocking solution (PBS containing 10% normal goat serum and 0.2% Triton X 100) for 1 hr. To block background staining from endogenous mouse IgG, the tissue sections were incubated with goat anti-mouse IgG1 Fab (1:10 dilution; Jackson ImmunoResearch, West Grove, PA) for 1 hr. After blocking, the slides were incubated with mouse anti-JUNV nucleoprotein antibody, diluted 1:100 in blocking solution, for 24 hr. Finally, the slides were incubated for 1 hr with goat anti-mouse IgG (H+L)-HRP secondary antibody (1:100 dilution; Thermo Fisher Scientific, Waltham, MA) and developed using ImmPACT NovaRED Peroxidase Substrate (Vector Laboratories, Burlingame, CA) according to the manufacturer's specifications. The slides were counterstained with hematoxylin.

Susceptibility of hTfR1 HOM mice lacking type I IFN receptor, or both type I and type II IFN receptors, to JUNV infection {#s4-10}
-------------------------------------------------------------------------------------------------------------------------

Cohorts of 3-week-old mice (*n* = 3/group) representing 6 different genetic profiles (WT, IFN-α/βR-deficient, IFN-α/β and -γR-deficient, hTfR1 HOM, hTfR1 HOM--IFN-α/βR-deficient and hTfR1 HOM--IFN-α/β and -γR-deficient) were challenged i.p. with 10^5^ CCID~50~ JUNV. The number of mice per group was based on power analysis performed using commonly accepted values for type I error (0.05) and power (80%). After challenge, the animals were weighed and assigned a clinical score daily for 28 days. At the end of the study, serum and tissues were collected from the surviving animals and assessed for viral burden.

Blockade of the type I IFN receptor in hTfR1 HOM mice and susceptibility to JUNV infection {#s4-11}
------------------------------------------------------------------------------------------

Three-week-old hTfR1 HOM mice were weighed the day before JUNV challenge and assigned to experimental groups (*n* = 3--4/virus challenge group, *n* = 3 for the sham-infected group) to minimize sex and weight differences across the groups. The number of mice per group was based on power analysis performed using commonly accepted values for type I error (0.05) and power (80%). The mice were administered anti-IFN-α/βR mAbs (500 μg; MAR1-5A3; Bio X Cell, West Lebanon, NH) or placebo (PBS vehicle only) via i.p. injection, 24 hr before i.p. challenge with 10^5^ CCID~50~ of JUNV. Following infection, specified groups of mice received additional i.p. injections of 250 μg of the anti-IFN-α/βR mAb or placebo every other day for 1 or 2 weeks. The animals were weighed and scored for clinical disease presentation daily for 28 days. At the conclusion of the study, serum and tissues were harvested from the surviving animals and viral loads determined.

Statistical analysis {#s4-12}
--------------------

The log-rank test was used for the analysis of Kaplan-Meier survival curves. A one-way analysis of variance (ANOVA) with Dunnett's multiple comparisons test was performed to compare differences in serum IFN-α concentrations. Weight change curves of groups where all animals survived were compared by two-way repeated-measures ANOVA with Sidak multiple comparisons test. All statistical evaluations were performed using Prism 8 (version 8.4.1). Results were considered significant if p≤0.05.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Current animal models of arenavirus pathogenesis are either not particularly robust or lack broad tractability. This study establishes a new mouse model of lethal Junin virus infection that recapitulates many key features of Junin virus pathogenesis in humans and may have broad utility for the development of vaccines and therapeutics targeting this important human pathogen.

**Decision letter after peer review:**

Thank you for submitting your article \"Type I interferon underlies severe disease associated with Junin virus infection in mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Karla Kirkegaard as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Juan Carlos de la Torre (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The New World mammarenavirus Junin (JUNV) is the causative agent of Argentine hemorrhagic fever (AHF), a disease endemic to the Pampas region of Argentina that is associated with severe clinical symptoms including hemorrhagic and neurological manifestations and a case fatality rate of 15-30% in patients who do not receive appropriate supportive treatment. In addition, JUNV possesses features that make it a credible biodefense threat. Therefore, the importance of developing vaccines and therapeutics to counteract JUNV infections and associated disease. The availability of a mouse model of JUNV infection would facilitate the development of therapeutics and vaccines against AHF disease, as well as a better understanding of the molecular and cellular bases underlying JUNV pathogenesis.

Here, the authors use transgenic mice expressing TfnR, a Junin virus entry factor, to establish an immunocompetent mouse model of Junin virus infection that recapitulates several disease outcomes observed in humans. Lethal disease in infected mouse was associated with increased type I interferon responses, demonstrating a key pathological feature of human disease in these mice. The pathogenic effects could be mitigated in mice lacking IFN receptors, or in mice treated with IFN receptor blocking antibody.

Essential revisions:

1\) The authors state that type I IFN underlies disease in this mouse model, but this is only demonstrated in young mice. Was viremia and serum IFN levels ever examined in older mice? Are these older mice just not replicating the virus, or is the virus replicating, but the mice are not making IFN? If the latter, would recombinant IFN treatment + Junin virus synergize in older mice to give a lethal phenotype?

2\) Tissue viral loads shown in Figure 7D and 8D provide no information regarding the contribution of viral loads to pathogenesis, because they were measured at the late time period and because controls are missing. To be meaningful, viral loads should be measured at 11 or 12 dpi including control groups: hTfR1+/+ (7D) and \"Placebo Tx\" (8D) groups. Related to this issue, the authors stated \"in the absence of a type I IFN response during the acute JUNV infection period hTfR1+/+ mice failed to clear the virus despite no apparent signs of illness\". For this to be true, viral loads should be compared to those of control groups. In addition, 6 or 3-4 mice in Figure 7 and 8, respectively, may provide statistically significant survival data, but when population variance is huge like the viral loads in Figure 7D and 8D, 3-6 mice is not nearly sufficient. In order to use right sample size, power and sample size calculation should be redone based on the preliminary data in 7D and 8D.

3\) Although hTfR1+/+ mice and IFNa/bR-/- and IFNa/bgR-/- mice are in different genetic background, they were backcrossed only twice. The authors\' conclusion of type I IFN response being the key element for JUNV pathogenesis is partially based on the data obtained using these mice with mosaic genetic background (Figure 7). Combined with the data in Figure 8, this conclusion may still be valid, but nonetheless the authors should indicate contaminating 129 genes could have contributed to the susceptibility to viral infection and tissue viral loads.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your article \"Type I interferon underlies severe disease associated with Junín virus infection in mice\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Karla Kirkegaard as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

The responses provided by the authors are overall reasonable, and they have incorporated changes to the text of the revised version of the paper that address many, but not all, the criticisms raised during the review of the originally submitted paper.

Revisions:

In lieu of additional experiments to address outstanding questions, the reviewers request that the authors expand the Discussion along the following lines:

A general suggestion is for the authors to add some useful topic sentences to the Discussion and, most importantly, conclude with a discussion of any other viral infections for which type 1 interferons contribute to pathogenesis.

More specifically, the authors should provide a more elaborated comparison between the mouse model of lethal JUNV infection and the NZB and FVB mouse models of LCMV infection where type I interferon was shown to be a critical factor for fatal outcome of infection.

10.7554/eLife.55352.sa2

Author response

> Essential revisions:
>
> 1\) The authors state that type I IFN underlies disease in this mouse model, but this is only demonstrated in young mice. Was viremia and serum IFN levels ever examined in older mice? Are these older mice just not replicating the virus, or is the virus replicating, but the mice are not making IFN? If the latter, would recombinant IFN treatment + Junin virus synergize in older mice to give a lethal phenotype?

The questions posed by the reviewers are of great interest and will pursued in future studies. Because our focus was to develop and characterize a lethal disease model of JUNV infection in hTfR1 mice, we did not characterize the infection in older age groups of mice that were refractory to disease. With that said, the weight loss observed in the 5-week-old hTfR1 mice challenged with JUNV suggests that there was viral replication in the older mice, which would most likely be accompanied by type I IFN induction. Studies by Ross and coworkers (Lavanya et al., Sci Transl Med, 2013; Cuevas and Ross, J Virol, 2014) have shown that the attenuated JUNV Candid\#1 vaccine strain can replicate in 4 and 8 to 10-week-old mice with spleen infectious virus titers present on days 8 and 7 p.i., respectively, suggesting that the more virulent JUNV Romero strain used in our studies would likely replicate to higher titers and for a longer period of time in older mice expressing hTfR1.

> 2\) Tissue viral loads shown in Figure 7D and 8D provide no information regarding the contribution of viral loads to pathogenesis, because they were measured at the late time period and because controls are missing. To be meaningful, viral loads should be measured at 11 or 12 dpi including control groups: hTfR1+/+ (7D) and \"Placebo Tx\" (8D) groups.

Ideally, we would have liked to include additional animals in each group that would be euthanized just prior to when the control groups (hTfR1+/+ or Placebo Tx) would be expected to succumb for evaluation of serum and tissue viral loads. Due to our animal and mAb limitations, we were not able to add the additional viral load arms to the studies.

Although the D panels of Figures 7 and 8 do not provide information regarding the contributions of viral loads to the disease process, the data indicate that mice with compromised type I, or compromised type I and type II, IFN responses do not clear JUNV by the end of the 28-day study period. Further studies are needed to investigate long-term persistence which could provide insights into the virus-host reservoir relationship.

> Related to this issue, the authors stated \"in the absence of a type I IFN response during the acute JUNV infection period hTfR1+/+ mice failed to clear the virus despite no apparent signs of illness\". For this to be true, viral loads should be compared to those of control groups.

This statement has been removed from the manuscript as part of the extensive revision. We now include the following statement. "Despite the lack of observable disease in the absence of IFN-α/β or IFN-α/β and γ receptors, or following temporary mAb blockade of the IFN-α/βR, JUNV was able to persist in hTfR1 mice for up to 28 days in multiple tissues." (fourth to the last sentence of the second paragraph of the Discussion)

> In addition, 6 or 3-4 mice in Figure 7 and 8, respectively, may provide statistically significant survival data, but when population variance is huge like the viral loads in Figure 7D and 8D, 3-6 mice is not nearly sufficient. In order to use right sample size, power and sample size calculation should be redone based on the preliminary data in 7D and 8D.

The purpose of the end-of-study sample collection was to qualitatively address the question of whether or not the surviving mice had cleared the JUNV infection. Future studies investigating longer-term persistence will be powered to determine statistical significance comparing titers from the different genotypes based on the findings reported in Panels 7D and 8D.

> 3\) Although hTfR1+/+ mice and IFNa/bR-/- and IFNa/bgR-/- mice are in different genetic background, they were backcrossed only twice. The authors\' conclusion of type I IFN response being the key element for JUNV pathogenesis is partially based on the data obtained using these mice with mosaic genetic background (Figure 7). Combined with the data in Figure 8, this conclusion may still be valid, but nonetheless the authors should indicate contaminating 129 genes could have contributed to the susceptibility to viral infection and tissue viral loads.

This is an excellent point. We have addressed this oversight by the addition of the following statement to the Results text. "Because of the hybrid background of the genotypic variants of mice used in the initial experiment to assess the role of the type I IFN response in JUNV pathogenesis, we could not rule out the contribution of genetic variation in susceptibility to JUNV infection, disease and persistence." (first sentence of last paragraph of the Results section)

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Revisions:
>
> In lieu of additional experiments to address outstanding questions, the reviewers request that the authors expand the Discussion along the following lines:
>
> A general suggestion is for the authors to add some useful topic sentences to the Discussion and, most importantly, conclude with a discussion of any other viral infections for which type 1 interferons contribute to pathogenesis.
>
> More specifically, the authors should provide a more elaborated comparison between the mouse model of lethal JUNV infection and the NZB and FVB mouse models of LCMV infection where type I interferon was shown to be a critical factor for fatal outcome of infection.

As suggested, we have added useful topic sentences to the Discussion.

Importantly, we have added text to paragraphs two, three and four of the Discussion, specifically elaborating on the comparison between the mouse JUNV infection model and the NZB and FVB mouse models of LCMV infection.
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